Spots Global Cancer Trial Database for temozolomide (tmz)
Every month we try and update this database with for temozolomide (tmz) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | NCT04421378 | Glioblastoma Mu... | Selinexor Temozolomide (T... Lomustine (CCNU... Standard Fracti... Bevacizumab TTField Carmustine | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma | NCT01390948 | High Grade Glio... | Bevacizumab Radiotherapy Temozolomide (T... | 6 Months - 18 Years | Hoffmann-La Roche | |
| A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma | NCT00395070 | Metastatic Mela... | Allovectin-7® Dacarbazine (DT... Temozolomide (T... | 18 Years - | Vical | |
| Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma | NCT03535350 | Glioblastoma | Ibrutinib Radiation Temozolomide (T... | 18 Years - | Case Comprehensive Cancer Center | |
| Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET | NCT02231762 | Gastroenteropan... | Lanreotide Auto... Temozolomide (T... | 18 Years - | Ipsen | |
| Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma | NCT03535350 | Glioblastoma | Ibrutinib Radiation Temozolomide (T... | 18 Years - | Case Comprehensive Cancer Center | |
| Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) | NCT01587144 | Glioblastoma Mu... | Lucanthone Temozolomide (T... Radiation Placebo | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) | NCT03405792 | Glioblastoma Glioblastoma, W... | Temozolomide (T... Optune System Pembrolizumab | 18 Years - 80 Years | University of Florida | |
| TTField in Combination With TMZ and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. | NCT06353360 | Glioblastoma Mu... | Tumor Treating ... Tislelizumab Temozolomide (T... | 18 Years - | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | |
| Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | NCT02942264 | Brain Tumor Astrocytoma Astroglioma Glioblastoma Gliosarcoma | Zotiraciclib (T... Temozolomide (T... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | NCT04752813 | Glioblastoma Glioblastoma Mu... | BPM31510 Vitamin K1 Temozolomide (T... Radiation | 18 Years - | Berg, LLC | |
| Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas | NCT02263105 | High-grade Glio... | CDDP Temozolomide | 18 Years - 75 Years | Huashan Hospital | |
| Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma | NCT00591370 | Melanoma | Temozolomide (T... | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | NCT04457284 | Colorectal Aden... | Temozolomide (T... Cisplatin Nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) | NCT03396575 | Diffuse Intrins... Brain Stem Glio... | TTRNA-DC vaccin... TTRNA-xALT Cyclophosphamid... Dose-Intensifie... Td vaccine Autologous Hema... | 3 Years - 30 Years | University of Florida | |
| Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients | NCT03212742 | Malignant Gliom... Radiotherapy PARP Inhibitor | Olaparib Temozolomide (T... IMRT (Intensity... | 18 Years - 70 Years | Centre Francois Baclesse | |
| Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) | NCT01587144 | Glioblastoma Mu... | Lucanthone Temozolomide (T... Radiation Placebo | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) | NCT03405792 | Glioblastoma Glioblastoma, W... | Temozolomide (T... Optune System Pembrolizumab | 18 Years - 80 Years | University of Florida | |
| Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients | NCT00525031 | Melanoma | Temozolomide (T... Pegylated Inter... | 18 Years - | M.D. Anderson Cancer Center | |
| Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma | NCT04388475 | Recurrent Malig... Brain Glioblast... | OKN-007 Temozolomide (T... | 18 Years - | Oblato, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
